Multicenter, Randomized Double-blind Study to Compare the Safety and Performance of a Combination of A-PRP and XLHA Prepared With the RegenMatrix Medical Device, to Hylan G-F 20 XLHA and Placebo to Treat Moderate/Severe Knee Osteoarthritis
概览
- 阶段
- 不适用
- 干预措施
- Regen Matrix-PRP-XLHA
- 疾病 / 适应症
- Knee Osteoarthritis
- 发起方
- RegenLab France SAS
- 入组人数
- 280
- 试验地点
- 13
- 主要终点
- Variation in the osteoarthritis related pain
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
In this clinical trial the investigator assess the safety and efficacy of a single injection of a combination of cross-linked hyaluronic acid (HA) with autologous platelet-rich plasma (PRP) obtained with the RegenMatrix medical device to improve symptoms of moderate to severe knee osteoarthitis (grade III-IV Kellgren-Lawrence).
详细描述
In this multicenter, randomized, double-blind, three-arm study, the investigator propose to evaluate the safety and efficacy at Day0, Month1, Month3 and Month6 of a single intra-articular injection of a combination RM-PRP-XLHA (experimental treatment: combination of cross-linked HA and PRP obtained with the RegenMatrix medical device) against Hylan G-F 20 (reference treatment) and placebo for the treatment of moderate to severe knee osteoarthritis. The symptomatic benefit will be evaluated in terms of pain reduction and improvement of patient's quality of life. The functional benefit of the treatment will also be evaluated, on a reduced number of participants, by a gait analysis, performed only in the coordinating centre. The medical device RegenMatrix is an adaptation of the medical device Cellular Matrix (certified since 2013,CE2797). It differs from the latter only for by presence of cross-linked HA instead of linear HA, and is therefore particularly suitable for the treatment of moderate to severe knee osteoarthritis.
研究者
入排标准
入选标准
- •Tibiofemoral knee osteoarthrosis according to ACR criteria
- •Tibiofemoral knee osteoarthrosis grade 3-4 according to the Kellgren \& Lawrence grading scale, as defined on knee radiographs (less than 3 months old: face view, schuss view, profile and patellar axial view at 30°)
- •Symptomatic knee osteoarthrosis as evidenced by pain on walking (WOMAC A1 assessed in the last 24 hours on a scale of 0 to 100 mm: 50 ≤ DM 90 or reduced joint function (WOMAC C total score assessed or within the previous 24 hours based on a scale of 0-100-mm: 50 ≤ WOMAC C ≤ 90)
- •Patient able to understand the requirements of the trial and who has signed a free and informed consent prior to study entry
- •Patient able to read and understand the written instructions
- •Patient able to complete the self-assessment questionnaires
排除标准
- •Tibiofemoral knee osteoarthrosis grade I or II according to the Kellgren and Lawrence grading scale
- •Knee surgery planned in the next 6 months
- •Patient affected by autoimmune disease (rheumatoid arthritis, lupus, Hashimoto's disease and Bechterew's syndrome)
- •Chronic inflammatory rheumatism other than arthritis (polyarthrosis, etc.)
- •Patient affected by a knee infection in the past 6 months
- •Clinical signs of local knee inflammation (redness or warmth of the knee joint)
- •Last PRP or PRP/HA injection received in the last year
- •Last viscosupplementation received in the past 6 months
- •Last corticosteroid injection received in the past 3 months
- •Use of gluco-corticosteroids (except inhaled) and level III analgesics in the last 3 months and non-steroidal anti-inflammatory drug in the last 2 weeks
研究组 & 干预措施
RegenMatrix-PRP-XLHA
Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
干预措施: Regen Matrix-PRP-XLHA
Hylan G-F 20
Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
干预措施: Hylan G-F 20
Placebo
Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)
干预措施: Placebo
结局指标
主要结局
Variation in the osteoarthritis related pain
时间窗: 6 months (Day 0 - Month 6)
It will be assessed by the mean difference in the WOMAC A score on a 100-mm VAS overtime
次要结局
- Variation of joint function during daily activity(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Variation in the osteoarthritis related symptoms(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Variation of patient's quality of life(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Pain, function, patient's general assessment(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Assessment of the minimal meaningful change according to the patient's perception(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Assessment of the highest level of symptom beyond which patients consider themselves well.(Month 1, Month 3 and Month 6 (D0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Variation in the overall osteoarthritis related pain(M1 and M3 (Day 0-Month 1; Day 0 - Month 3))
- Variation of joint stiffness after the first awakening and later in the day(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))
- Rescue medication(Month 1, Month 3 and Month 6 (Day 0-Month 1; Day 0-Month 3; Day 0-Month 6))